Medicare Enrolled
Dr. Ma Theresa Egasani-Elises, MD
Family Medicine · Walnut Creek, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Egasani-Elises from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Egasani-Elises?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Egasani-Elises
Dr. Ma Theresa Egasani-Elises is a family medicine specialist in Walnut Creek, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Egasani-Elises performed 3,110 Medicare services across 999 unique beneficiaries.
Between the years covered by Open Payments, Dr. Egasani-Elises received a total of $14,198 from 66 pharmaceutical and/or device companies across 693 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Egasani-Elises is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 6% volume in CA
$14,198 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,110
Medicare services
Top 6% in CA for family medicine
999
Unique beneficiaries
$37
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~183 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,680 | $19 | $54 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
594 | $68 | $305 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
213 | $61 | $210 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
140 | $56 | $312 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
79 | $3 | $19 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
77 | $13 | $75 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
57 | $76 | $127 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
57 | $36 | $70 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
46 | $82 | $406 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
35 | $13 | $106 |
| COVID-19 vaccine administration Administration of a single dose of the coronavirus vaccine. |
21 | $48 | $120 |
| COVID-19 vaccine (Pfizer bivalent) Administration of a 30 mcg dose of the SARS-CoV-2 vaccine via intramuscular injection. |
21 | $128 | $394 |
| Respiratory virus detection test A laboratory test using immunoassay techniques to detect the presence of severe acute respiratory syndrome coronavirus and influenza viruses. |
20 | $40 | $188 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
15 | $50 | $97 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
15 | $283 | $381 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
14 | $44 | $133 |
| Influenza virus detection test A laboratory test that uses an immunoassay technique to detect the presence of the influenza virus through direct visual observation. |
13 | $16 | $64 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
13 | $36 | $70 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$14,198
Total received (2018-2024)
Avg $2,028/year across 7 years
Top 3% in CA for family medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
693
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,043 (98.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$155 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,707
2023
$2,611
2022
$2,302
2021
$2,649
2020
$1,520
2019
$1,742
2018
$667
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$516
Lilly USA, LLC
$361
Boehringer Ingelheim Pharmaceuticals, Inc.
$253
AstraZeneca Pharmaceuticals LP
$244
PFIZER INC.
$171
Novo Nordisk Inc
$170
Currax Pharmaceuticals LLC
$143
Astellas Pharma US Inc
$132
Otsuka America Pharmaceutical, Inc.
$120
Mannkind Corporation
$88
Ascensia Diabetes Care Us Inc.
$63
GlaxoSmithKline, LLC.
$60
IBSA Pharma Inc.
$48
ABBVIE INC.
$48
Dexcom, Inc.
$33
Vanda Pharmaceuticals Inc.
$31
Dynavax Technologies Corporation
$25
Averitas Pharma Inc.
$25
Xeris Pharmaceuticals, Inc.
$23
Bayer Healthcare Pharmaceuticals Inc.
$22
Sumitomo Pharma America, Inc.
$22
Abbott Laboratories
$20
Phadia US Inc.
$19
Optinose US, Inc.
$19
Radius Health, Inc.
$18
Bausch Health US, LLC
$16
Lundbeck LLC
$13
Top 3 companies account for 41.8% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$2,181
Novo Nordisk Inc
$1,182
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,083
Lilly USA, LLC
$968
PFIZER INC.
$956
AbbVie Inc.
$880
Amarin Pharma Inc.
$779
AstraZeneca Pharmaceuticals LP
$629
Otsuka America Pharmaceutical, Inc.
$364
IBSA Pharma Inc.
$343
ABBVIE INC.
$321
SANOFI-AVENTIS U.S. LLC
$296
Bayer Healthcare Pharmaceuticals Inc.
$258
Radius Health, Inc.
$240
Allergan, Inc.
$231
Abbott Laboratories
$213
Mannkind Corporation
$205
Corcept Therapeutics
$186
GlaxoSmithKline, LLC.
$184
Currax Pharmaceuticals LLC
$172
Merck Sharp & Dohme Corporation
$159
Biohaven Pharmaceuticals, Inc.
$156
Bausch Health US, LLC
$140
Astellas Pharma US Inc
$132
Takeda Pharmaceuticals U.S.A., Inc.
$126
Biohaven Pharmaceutical Holding Company Ltd.
$124
Bayer HealthCare Pharmaceuticals Inc.
$116
Exact Sciences Corporation
$116
Horizon Therapeutics plc
$97
Janssen Pharmaceuticals, Inc
$89
MannKind Corporation
$84
Merck Sharp & Dohme LLC
$79
Xeris Pharmaceuticals, Inc.
$75
Endo Pharmaceuticals Inc.
$72
Alexion Pharmaceuticals, Inc.
$71
Dexcom, Inc.
$65
Ascensia Diabetes Care Us Inc.
$63
Teva Pharmaceuticals USA, Inc.
$63
Averitas Pharma Inc.
$51
Gilead Sciences, Inc.
$51
Ipsen Biopharmaceuticals, Inc
$43
Phadia US Inc.
$36
Vanda Pharmaceuticals Inc.
$31
Ascendis Pharma Inc
$31
Amryt Pharma Holdings Ltd
$30
Companion Medical, Inc.
$29
Embecta Corp.
$27
Insulet Corporation
$26
Dynavax Technologies Corporation
$25
Esperion Therapeutics, Inc.
$24
Allergan Inc.
$24
AMAG Pharmaceuticals, Inc.
$23
VBI Vaccine (Delaware) Inc.
$22
Sumitomo Pharma America, Inc.
$22
Antares Pharma, Inc.
$21
LifeScan, Inc.
$20
CeQur Corporation
$19
Focal Therapeutics, Inc.
$19
Mylan Pharmaceuticals Inc.
$19
Optinose US, Inc.
$19
Tandem Diabetes Care, Inc.
$18
Synergy Pharmaceuticals Inc
$17
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$16
AbbVie, Inc.
$14
Nabriva Therapeutics, plc
$13
Lundbeck LLC
$13
Top 3 companies account for 31.3% of all-time payments
Associated products mentioned in payments ›
AFREZZA · AIRSUPRA · AJOVY · APLENZIN · Aimovig · BAQSIMI · BD Nano 2nd Gen Pen Needle · BEXSERO · BREO · BREZTRI · Biozorb · CHANTIX · COLOGUARD · COLOGUARD DNA CAPTURE REAGENTS · CONTRAVE · CYCLOSET · CeQur Simplicity · Cologuard Collection Kit · DIFICID · Descovy · Dexcom G6 Transmitter · ELIQUIS · EMGALITY · EUCRISA · EVENITY · EVERSENSE E3 SENSOR KIT - RETAIL · EVUSHELD · FARXIGA · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre 2 · GEMTESA · GVOKE HYPOPEN · HETLIOZ · Heplisav-B · INTRAROSA · INVEGA SUSTENNA · INVOKANA · ImmunoCAP · InPen · JANUVIA · JARDIANCE · Kerendia · Korlym · LICART · LO LOESTRIN FE · LYRICA · MOUNJARO · MYCAPSSA · MYFEMBREE · NASCOBAL · NEXLETOL · NURTEC ODT · ONZETRA XSAIL · OT Verio Reflect "One Touch Meter and Strips" · Omnipod · Otezla · Otrexup · Ozempic · PAXLOVID · PNEUMOVAX 23 · PREMARIN · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · PreHevbrio · Prolia · QULIPTA · QUTENZA · QVAR · RECORLEV · REXULTI · RYBELSUS · Repatha · Rybelsus · SHINGRIX · SOLIQUA 100/33 · SPIRIVA RESPIMAT · STRENSIQ · SYMBICORT · SYNTHROID · Saxenda · Somatuline Depot · Strensiq · Synthroid · TEPEZZA · TOUJEO · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · Tirosint · Tresiba · Trintellix · Trulance · Tymlos · UBRELVY · VRAYLAR · Vascepa · Veozah · Wegovy · XARELTO · Xenleta · Xhance · Xulane · ZEPBOUND · ZOSTAVAX · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 3% for family medicine in CA.
Geographic Context
Family medicine physicians within 10 mi
1,445
Per 100K population
124.4
County median income
$125,727
Nearest hospital
KAISER FOUNDATION HOSPITAL - WALNUT CREEK
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Egasani-Elises is a clinical cardiology specialist, with above-average Medicare volume (top 6% in CA), with low-engagement industry engagement in the top 3% of CA peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Egasani-Elises experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Egasani-Elises performed 1,680 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Egasani-Elises receive payments from pharmaceutical companies?
Yes. Dr. Egasani-Elises received a total of $14,198 from 66 companies across 693 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Egasani-Elises's costs compare to other family medicine physicians in Walnut Creek?
Dr. Egasani-Elises's average Medicare payment per service is $37. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Egasani-Elises) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicine Physicians in Walnut Creek
Browse family medicine physicians in Walnut Creek ranked by procedure volume and transparency data.
Highest volume
Top Family Medicine Physicians in CA
Family medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicine Physicians in CA
Which CA family medicine physicians receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology